key: cord-0770221-qhcmbx2g
authors: Pavia, G.; Gargiulo, L.; Spinelli, F.; Avagliano, J.; Valenti, M.; Borroni, R. G.; Costanzo, A.; Narcisi, A.
title: Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab
date: 2022-03-03
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.18032
sha: df17a77c95e7a93a5c7fe7b92fa635fe000d9b15
doc_id: 770221
cord_uid: qhcmbx2g

nan

to our Emergency Department with an exacerbation of psoriasis after the second dose of BNT162b2 COVID-19 vaccine. The patient referred the rapid worsening of her psoriasis, starting from 10 days after the vaccination (Second dose inoculated on 23 May 2021). She was on treatment with ustekinumab 90 mg since 2016, and she skipped the scheduled administration in May 2021. She was also affected by obesity and psoriatic arthritis; she was previously treated with infliximab, discontinued for intolerance. On physical examination, we observed wide erythematous plaques confluent to both the trunk and the four limbs, covered by large scales. The PASI was 29.8 and the involved body surface was more than the 30% of the total area. She had fever (38.2°C) and arthralgias; blood examinations showed 11 000/ mm 3 white cells, C-reactive protein 14.56 mg/dL. After the hospitalization, blood cultures at the febrile peak returned negative; and 2 days later, we observed numerous small pustules surrounding the erythematous scaling plaques, although the pustular eruption was particularly intense on the cutaneous folds. The clinical appearance was suggestive for a flare of generalized pustular psoriasis (GPP) superimposed on a plaque psoriasis, and we supposed the relationship with the second shot of BNT162b2 COVID-19 vaccine. During the hospitalization, the pustules became larger, coalescent and thicker, involving also patient's palms and soles; few patches began to ulcerate and the scaly plaques involved also the face and the scalp (Figs. 1 and 2a,  b) . Tumour markers for malignancy were negative. Having considered the risk of a superimposed infection, the comorbidities and the severity of the psoriasis, we therefore decided to start therapy with risankizumab 75 mg/fl with two subcutaneous injections, while an oral therapy with daptomycin 850 mg/day was prescribed. One week after the first dose of risankizumab, the pustular eruption disappeared and after 2 weeks of hospitalization the plaques improved, with only slight erythema. She received the second dose of risankizumab and to date she is still on therapy, having achieved the complete disease control (PASI 0) at Week 16 (Fig. 2c) .

Flare-up of plaque psoriasis in the setting of SARS-CoV2 infection 3 and after COVID-19 vaccines is widely described in literature, usually resolving after few weeks but, sometimes, needing rescue therapies. 4 therapy, we prescribed risankizumab, a IL-23 inhibitor, since our patient was intolerant to infliximab, previously on optimal therapy with ustekinumab, affected by severe obesity and at risk of superimposed infections. In conclusion, we described GPP flare and exacerbation of psoriasis in a patient who previously received BNT162b2 vaccine: this could probably be a rare adverse reaction related to COVID-19 vaccine, in a patient who interrupted the biological therapy. Since the high rate of comorbidities in psoriatic patients, the vaccination should be strongly recommended in this population. On the other hand, dermatologists should keep in mind the possibility of rare flare-up of preexisting dermatoses or the onset of new cutaneous manifestations in genetically predisposed patients. No guidelines are currently available concerning the management of a GPP flare after COVID-19 vaccine, and further cases should be collected to deepen our knowledge.

COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry based study of 414 cases

New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019

Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases

Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine

Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre

New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin?

Comment on 'De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine': possible role for Type I interferons

Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine

The patient in this manuscript gave written informed consent to publication of her case details.